The estimated Net Worth of Serge Saxonov is at least $37.8 Milión dollars as of 22 August 2024. Mr. Saxonov owns over 6,749 units of 10x Genomics stock worth over $19,502,521 and over the last 5 years he sold TXG stock worth over $15,906,575. In addition, he makes $2,362,960 as Chief Executive Officer, Co-Founder a Director at 10x Genomics.
Sign up
Mr. Saxonov TXG stock SEC Form 4 insiders trading
Serge has made over 61 trades of the 10x Genomics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 6,749 units of TXG stock worth $152,055 on 22 August 2024.
The largest trade he's ever made was exercising 56,363 units of 10x Genomics stock on 28 December 2021 worth over $67,636. On average, Serge trades about 7,612 units every 24 days since 2019. As of 22 August 2024 he still owns at least 882,467 units of 10x Genomics stock.
You can see the complete history of Mr. Saxonov stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Serge Saxonov biography
Serge Wilson Saxonov Ph.D. was President, Chief Executive Officer, Co-Founder, Director of the Company. He co-founded 10x Genomics and has served as our Chief Executive Officer and on our board of directors since July 2012. Dr. Saxonov also served as our President from July 2012 until October 2012. Prior to co-founding our company, Dr. Saxonov was Vice President of Applications at QuantaLife, a privately-held life sciences company that developed and commercialized a droplet digital polymerase chain reaction platform, from May 2010 to April 2012. Dr. Saxonov was Founding Architect and Director of research and development at 23andMe, a privately held personal genomics and biotechnology company, from June 2006 until May 2010. Dr. Saxonov received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.
What is the salary of Serge Saxonov?
As the Chief Executive Officer, Co-Founder a Director of 10x Genomics, the total compensation of Serge Saxonov at 10x Genomics is $2,362,960. There are no executives at 10x Genomics getting paid more.
How old is Serge Saxonov?
Serge Saxonov is 43, he's been the Chief Executive Officer, Co-Founder a Director of 10x Genomics since 2012. There are 15 older and 1 younger executives at 10x Genomics. The oldest executive at 10x Genomics, Inc. is John Stuelpnagel, 62, who is the Independent Chairman of the Board.
What's Serge Saxonov's mailing address?
Serge's mailing address filed with the SEC is 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588.
Insiders trading at 10x Genomics
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F... a Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
What does 10x Genomics's logo look like?
Complete history of Mr. Saxonov stock trades at 10x Genomics
10x Genomics executives and stock owners
10x Genomics executives and other stock owners filed with the SEC include:
-
Serge Saxonov,
Chief Executive Officer, Co-Founder, Director -
Benjamin Hindson,
President, Co-Founder, Chief Scientific Officer, Director -
Sridhar Kosaraju,
Independent Director -
Shehnaaz Suliman,
Independent Director -
Eric Whitaker,
General Counsel -
Bryan Roberts,
Independent Director -
Dr. Serge Saxonov Ph.D.,
Co-Founder, CEO & Director -
Justin McAnear,
Chief Financial Officer -
Dr. Benjamin J. Hindson Ph.D.,
Co-Founder, Pres, Chief Scientific Officer & Director -
Bradford J. Crutchfield,
Chief Commercial Officer -
Ruth De Backer,
Chief Bus. Officer -
Justin J. McAnear,
Chief Financial Officer -
John Stuelpnagel,
Independent Chairman of the Board -
Mathai Mammen,
Independent Director -
Kimberly Popovits,
Independent Director -
Bradford Crutchfield,
Chief Commercial Officer -
Jean Philibert,
Chief People Officer -
Sam Ropp,
Sr. VP of Global Sales -
Jonathan Schimmel,
VP of Global Support & Sales Operations -
Eric S. Whitaker,
Gen. Counsel -
Cassie Corneau,
Mang. of Investor Relations and Strategic Fin. -
Paul W. Wyatt,
Sr. VP of Operations -
Capital Management, Llc Pal...,
-
Associates Vi, L.P.Venrock ...,
-
Vision Fund (Aiv M2) L.P.Sb...,
-
Capital Management I, Llc F...,
-
Sarah A. Teichmann,
-
James Wilbur,
Chief Commercial Officer -
Alan Mateo,